INFLUENCE OF INTERFERON ON ANTIBODY-PRODUCTION AND VIABILITY OF MALIGNANT-CELLS FROM PATIENTS WITH MULTIPLE-MYELOMA

被引:0
|
作者
GRANDER, D
VONSTEDINGK, LV
VONSTEDINGK, M
WASSERMAN, J
EINHORN, S
机构
[1] KAROLINSKA HOSP,RADIUM HEMMET,DIV EXPTL ONCOL,S-10401 STOCKHOLM,SWEDEN
[2] STOCKHOLM CTY COUNCIL,CENT MICROBIOL LAB,STOCKHOLM,SWEDEN
关键词
CYTOTOXIC EFFECT; IMMUNOGLOBULIN PRODUCTION; INTERFERON; MYELOMA;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The influence of interferon (IFN) on antibody production and viability of malignant cells from patients with multiple myeloma was evaluated. Following incubation of bone marrow cells with IFN-alpha (5000 units/ml) for 7 days) a decreased production of monoclonal immunoglobin (mlg) was detected in all experiments except one. IFN induced a > 50% decrease in myeloma cell viability in 11 patients and a greater-than-or-equal-to 25% decrease in 4 patients, whereas in myeloma cells from 8 patients IFN had no or only minor effects. The observed effect was not due to an inhibition of proliferation since < 5% of the myeloma cells were labeled with [H-3]-thymidine during 7 d of culture. There was no statistically significant correlation between decreases in myeloma cell viability and effects on mlg production, exemplified by the fact that mlg production was decreased also in patients showing no sensitivity to IFN's cytotoxic action. Depletion of autologus T-cells, NK-cells and/or monocytes did not abrogate the effects observed. We conclude that IFN can reduce the viability of myeloma cells and the production of Ig from these cells and that the latter can be exerted without an antitumor effect.
引用
收藏
页码:17 / 25
页数:9
相关论文
共 21 条
  • [1] THE ONCOPROTEIN PHENOTYPE OF PLASMA-CELLS FROM PATIENTS WITH MULTIPLE-MYELOMA
    BROWN, RD
    POPE, B
    LUO, XF
    GIBSON, J
    JOSHUA, D
    LEUKEMIA & LYMPHOMA, 1994, 16 (1-2) : 147 - 156
  • [2] A CD10-POSITIVE SUBSET OF MALIGNANT-CELLS IS IDENTIFIED IN MULTIPLE-MYELOMA USING PCR WITH PATIENT-SPECIFIC IMMUNOGLOBULIN GENE PRIMERS
    CAO, J
    VESCIO, RA
    RETTIG, MB
    HONG, CH
    KIM, A
    LEE, JC
    LICHTENSTEIN, AK
    BERENSON, JR
    LEUKEMIA, 1995, 9 (11) : 1948 - 1953
  • [3] COMBINATION THERAPY WITH INTERFERON-DEXAMETHASONE FOR NEWLY-DIAGNOSED PATIENTS WITH MULTIPLE-MYELOMA
    DIMOPOULOS, MA
    WEBER, D
    DELASALLE, KB
    ALEXANIAN, R
    CANCER, 1993, 72 (09) : 2589 - 2592
  • [4] CHARACTERIZATION OF BONE-MARROW STROMAL CELLS FROM MULTIPLE-MYELOMA
    GREGORETTI, MG
    GOTTARDI, D
    GHIA, P
    BERGUI, L
    MERICO, F
    MARCHISIO, PC
    CALIGARISCAPPIO, F
    LEUKEMIA RESEARCH, 1994, 18 (09) : 675 - 682
  • [5] CD5 POSITIVE IMMUNOREGULATORY B-CELLS IN SPLEEN POPULATIONS FROM MULTIPLE-MYELOMA PATIENTS
    MACKENZIE, MR
    PAGLIERONI, T
    CAGGIANO, V
    AMERICAN JOURNAL OF HEMATOLOGY, 1991, 37 (03) : 163 - 166
  • [6] DETECTION OF MALIGNANT B-CELLS IN PERIPHERAL-BLOOD STEM-CELL COLLECTIONS AFTER CHEMOTHERAPY IN PATIENTS WITH MULTIPLE-MYELOMA
    DREYFUS, F
    RIBRAG, V
    LEBLOND, V
    RAVAUD, P
    MELLE, J
    QUARRE, MC
    PILLIER, C
    BOCCACCIO, C
    VARET, B
    BONE MARROW TRANSPLANTATION, 1995, 15 (05) : 707 - 711
  • [7] Effect of interferon-alpha on immunoglobulin production by peripheral blood mononuclear cells in multiple myeloma
    Saily, M
    Koistinen, P
    Laine, S
    Soppi, E
    Savolainen, ER
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1996, 57 (02) : 171 - 177
  • [8] MOLECULAR-DETECTION OF CLONALLY REARRANGED CELLS IN PERIPHERAL-BLOOD PROGENITOR-CELL HARVESTS FROM MULTIPLE-MYELOMA PATIENTS
    BIRD, JM
    BLOXHAM, D
    SAMSON, D
    MARCUS, RE
    RUSSELL, NH
    KELSEY, SM
    NEWLAND, AC
    APPERLEY, JF
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (01) : 110 - 116
  • [9] TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells
    Gazitt, Y
    LEUKEMIA, 1999, 13 (11) : 1817 - 1824
  • [10] TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells
    Y Gazitt
    Leukemia, 1999, 13 : 1817 - 1824